急性冠脉综合征抗凝治疗进展  

Advances in anticoagulant therapy after acute coronary syndrome

作　　者：饶明月[1] 王亚玲[1] 张国茹[1] 王梅[1] Rao Mingyue;Wang Yaling;Zhang Guoru;Wang Mei(Department of Cardiology,the Second Hospital of Hebei Medical University,Shijiazhuang 050000,China)

机构地区：[1]河北医科大学第二医院东院区心内一科,河北石家庄050000

出　　处：《临床荟萃》2018年第9期761-766,共6页Clinical Focus

摘　　要：冠状动脉粥样硬化斑块破裂或侵蚀导致的血管内皮损伤是冠脉病变处血栓形成的病理生理基础,急性冠状动脉综合征(acute coronary syndrome,ACS)的发生常常伴随着心电图的改变、心肌损伤标志物的升高和伴随着心绞痛症状的出现。抗血小板及抗凝治疗是ACS治疗的关键,有效地应用抗血小板及抗凝药物能降低心肌梗死、支架内血栓形成等缺血事件的发生及降低病死率。本文主要对ACS的抗凝药物治疗进展做一综述。Vascular endothelial damage caused by erosion or rupture of coronary atherosclerotic plaque is the pathophysiological basis of thrombosis in coronary artery lesions. The onset of acute coronary syndrome（ACS） is often accompanied by changes in electrocardiogram, increased markers of myocardial injury and the appearance of symptoms of angina pectoris. Antiplatelet and anticoagulant therapy is the key to the treatment of ACS. The effective use of antiplatclet and anticoagulant drugs can reduce the occurrence of ischemic events such as myocardial infarction, thrombosis in stent and a reduction in mortality. This article reviews current evidences for anticoagulants in ACS.

关 键 词：急性冠状动脉综合征 抗凝药 缺血 出血 

分 类 号：R542.2[医药卫生—心血管疾病]